SPENCER STANGER: Open Payments
NPI 1780194696 · RIGBY, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 45 payments from 21 companies in 2025. Trend: 2023 $415 · 2024 $1,125 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $179 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Lilly USA, LLC | 5 | $76 |
| Neuronetics, Inc. | 1 | $57 |
| Novo Nordisk Inc | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
Products named: VRAYLAR, FANAPT, MOUNJARO, NEUROSTAR TMS THERAPY SYSTEM, UBRELVY, CAPLYTA, Auvelity, XIFAXAN.
Industry payments across ID — which companies pay providers there.
